NSCLC Clinical Trials

43 studies are recruiting for nsclc in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)

   The purpose of this study is to see whether adding liver stereotactic ablative radiotherapy/L-SABR to standard drug therapy is better than standard drug therapy alone for people with metastatic non-small cell lung cancer/NSCLC.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   BAPTIST ALLIANCE - MCI (Data Collection Only), Miami, Florida

   Locations

   9 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05657873 on ClinicalTrials.gov

2. Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

   The purpose of this study is to test whether or not number of circulating cancer cells detected in the blood can be decreased the by combining the standard treatment (durvalumab) with Tremelimumab and additional chemotherapy

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Stanford University, Stanford, California

   Run by

   Maximilian Diehn

   See if you can join NCT04585490 on ClinicalTrials.gov

3. ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

   The purpose of this study is to establish the recommended phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-114 in combination with subcutaneous (SC) amivantamab in patients with advanced or metastatic NSCLC harboring an EGFR exon …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NYU Langone Health, New York, New York

   Locations

   4 in total

   Run by

   ORIC Pharmaceuticals

   See if you can join NCT06816992 on ClinicalTrials.gov

4. A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

   This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment opti…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

   Locations

   23 in total

   Run by

   Nested Therapeutics, Inc

   See if you can join NCT06326411 on ClinicalTrials.gov

5. A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

   This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study nea…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Colorado Cancer Center, Aurora, Colorado

   Locations

   5 in total

   Run by

   7 Hills Pharma, LLC

   See if you can join NCT06362369 on ClinicalTrials.gov

6. Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer

   Determine anti-tumor efficacy by characterizing response rates on positron emission tomography (PET) following three cycles of induction immunotherapy with cemiplimab and fianlimab without chemotherapy for locally advanced non-small cell lung cancer (LA-NSCLC).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Montefiore Einstein Comprehensive Cancer Center (MECCC), The Bronx, New York

   Run by

   Montefiore Medical Center

   See if you can join NCT06865339 on ClinicalTrials.gov

7. Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements

   This study will consist of a Phase 1b and Phase 2 portion. The Phase 1b portion will enroll first followed by the Phase 2 portion. Each cycle of treatment = 28 days. Subjects will receive alectinib twice daily. Those in the Phase 1b portion will receive alectinib alone. Those in Phase 2 Arm A will …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Stanford University, Stanford, California

   Locations

   3 in total

   Run by

   Joshua Palmer

   See if you can join NCT05987644 on ClinicalTrials.gov

8. Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

   This is a single arm phase 2 trial is to evaluate the efficacy of SRS plus adagrasib for the treatment of brain metastases for patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC). A total of 30 patients will be enrolled on this study.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Locations

   3 in total

   Run by

   Ryan Gentzler, MD

   See if you can join NCT06248606 on ClinicalTrials.gov

9. Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

   This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which n…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

   Locations

   12 in total

   Run by

   Vivace Therapeutics, Inc

   See if you can join NCT04665206 on ClinicalTrials.gov

10. A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

    The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Honor Health Research Institute, Scottsdale, Arizona

    Locations

    11 in total

    Run by

    Incendia Therapeutics

    See if you can join NCT05753722 on ClinicalTrials.gov

11. First in Human Study of TORL-1-23 in Participants With Advanced Cancer

    This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Providence Medical Foundation, Fullerton, California

    Locations

    14 in total

    Run by

    TORL Biotherapeutics, LLC

    See if you can join NCT05103683 on ClinicalTrials.gov

12. LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients

    This is a Single arm, Simon's two stage pilot study in which patients with Non-Small Cell Lung Cancer (NSCLC) with metastatic disease 2L and beyond will receive OncoChoice-informed chemotherapy following National Cancer Care Network (NCCN) treatment guidelines on dosage and scheduling for NSCLC FDA…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Illinois Cancer Center, Chicago, Illinois

    Run by

    University of Illinois at Chicago

    See if you can join NCT06576635 on ClinicalTrials.gov

13. Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer

    The purpose of this study is to learn the effects of fasting on cancer cells while you get maintenance treatment.

    Stage

    Not phased

    Ages

    18 and older

    Site

    VA Long Beach Healthcare System, Long Beach, CA, Long Beach, California

    Locations

    4 in total

    Run by

    VA Office of Research and Development

    See if you can join NCT06671613 on ClinicalTrials.gov

14. A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

    This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    9 in total

    Run by

    ImmVira Pharma Co. Ltd

    See if you can join NCT04370587 on ClinicalTrials.gov

15. APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

    To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring w…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California

    Locations

    35 in total

    Run by

    Apollomics Inc.

    See if you can join NCT03175224 on ClinicalTrials.gov

16. A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

    It is a Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0036 in Subjects with Advanced Solid Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Horizon Oncology, Lafayette, Indiana

    Locations

    4 in total

    Run by

    Shanghai Huaota Biopharmaceutical Co., Ltd.

    See if you can join NCT05417321 on ClinicalTrials.gov

17. Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

    Study CJB-101-01 will be conducted at multiple centers in the USA and Republic of Korea as an open-label safety and preliminary efficacy study of CJRB-101 in combination with pembrolizumab in subjects with selected types of advanced or metastatic cancer. The proposed study intends to address the un…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California, Irvine, Irvine, California

    Locations

    4 in total

    Run by

    CJ Bioscience, Inc.

    See if you can join NCT05877430 on ClinicalTrials.gov

18. Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC

    To test whether it is feasible to perform the 3D-EX functional predictive response bioassay in the context of patients with advanced/metastatic NSCLC receiving immune checkpoint inhibitors in the standard of care clinical setting.

    Stage

    Not phased

    Ages

    18 to 110

    Site

    The University of Kansas Cancer Center (KUCC), Fairway, Kansas

    Locations

    2 in total

    Run by

    Jun Zhang, MD, PhD

    See if you can join NCT05332925 on ClinicalTrials.gov